Literature DB >> 14565934

TCR-mediated hyper-responsiveness of autoimmune Galphai2(-/-) mice is an intrinsic naïve CD4(+) T cell disorder selective for the Galphai2 subunit.

Tiffany T Huang1, Yumei Zong, Harnisha Dalwadi, Chan Chung, M Carrie Miceli, Karsten Spicher, Lutz Birnbaumer, Jonathan Braun, Richard Aranda.   

Abstract

Heterotrimeric Gi signaling regulates immune homeostasis, since autoimmunity occurs upon disruption of this pathway. However, the role of the lymphocyte-expressed Galphai subunits (Galphai2 and 3) on T cell activation and cytokine production is poorly understood. To examine this role, we studied T lymphocytes from mice deficient in the Galphai2 or Galphai3 subunits. Galphai2(-/-) but not Galphai3(-/-) splenocytes were hyper-responsive for IFN-gamma and IL-4 production following activation through the TCR. Galphai2(-/-) T cells had a relaxed costimulatory requirement for IL-2 secretion and proliferation compared to wild-type cells. Purified naïve Galphai2(-/-) T cells produced more IL-2 than naïve wild-type T cells following TCR activation, indicating that the hyper-responsive cytokine profile was not due to the expanded Galphai2(-/-) memory T cells, but involved an intrinsic T cell alteration. Cytokine hyper-responsiveness was not seen when purified Galphai2(-/-) T cells were stimulated with phorbol myristic acetate/ionomycin, localizing the alteration to a proximal TCR-specific signaling pathway. Galphai2(-/-) CD4(+) T cells were distinguished from wild-type or Galphai3(-/-) T cells by a globally augmented TCR-induced calcium response. These findings indicate that Galphai2(-/-) mice have an intrinsic CD4(+) T cell abnormality in TCR signaling which may be one cause of augmented T cell effector function and Galphai2(-/-) autoimmune susceptibility.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14565934     DOI: 10.1093/intimm/dxg135

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  29 in total

Review 1.  Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models.

Authors:  Aya M Westbrook; Akos Szakmary; Robert H Schiestl
Journal:  Mutat Res       Date:  2010-03-16       Impact factor: 2.433

Review 2.  A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).

Authors:  Jerold Chun; Volker Brinkmann
Journal:  Discov Med       Date:  2011-09       Impact factor: 2.970

3.  Formation of B and T cell subsets require the cannabinoid receptor CB2.

Authors:  David Ziring; Bo Wei; Peter Velazquez; Matthew Schrage; Nancy E Buckley; Jonathan Braun
Journal:  Immunogenetics       Date:  2006-08-19       Impact factor: 2.846

4.  Integration of B cells and CD8+ T in the protective regulation of systemic epithelial inflammation.

Authors:  Bo Wei; Michael McPherson; Olga Turovskaya; Peter Velazquez; Daisuke Fujiwara; Sarah Brewer; Jonathan Braun
Journal:  Clin Immunol       Date:  2008-02-20       Impact factor: 3.969

5.  Aberrant T-cell ontogeny and defective thymocyte and colonic T-cell chemotactic migration in colitis-prone Galphai2-deficient mice.

Authors:  Kristina Elgbratt; Malin Bjursten; Roger Willén; Paul W Bland; Elisabeth Hultgren Hörnquist
Journal:  Immunology       Date:  2007-05-09       Impact factor: 7.397

6.  Requirement of Galphai in thymic homing and early T cell development.

Authors:  YongZhu Jin; Mei X Wu
Journal:  Mol Immunol       Date:  2008-05-23       Impact factor: 4.407

Review 7.  Implications of non-canonical G-protein signaling for the immune system.

Authors:  Cédric Boularan; John H Kehrl
Journal:  Cell Signal       Date:  2014-02-28       Impact factor: 4.315

8.  Defective chemokine signal integration in leukocytes lacking activator of G protein signaling 3 (AGS3).

Authors:  Melissa Branham-O'Connor; William G Robichaux; Xian-Kui Zhang; Hyeseon Cho; John H Kehrl; Stephen M Lanier; Joe B Blumer
Journal:  J Biol Chem       Date:  2014-02-26       Impact factor: 5.157

9.  Gαi2 and Gαi3 Differentially Regulate Arrest from Flow and Chemotaxis in Mouse Neutrophils.

Authors:  Yoshihiro Kuwano; Micha Adler; Hong Zhang; Alex Groisman; Klaus Ley
Journal:  J Immunol       Date:  2016-03-14       Impact factor: 5.422

10.  A single nucleotide polymorphism in Tyk2 controls susceptibility to experimental allergic encephalomyelitis.

Authors:  Karen M Spach; Rajkumar Noubade; Ben McElvany; William F Hickey; Elizabeth P Blankenhorn; Cory Teuscher
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.